HDL-Targeted Therapies During Myocardial Infarction

It is now apparent that a variety of deleterious mechanisms intrinsic to myocardial infarction (MI) exists and underlies its high residual lethality. Indeed, despite effective coronary patency therapies, ischemia and reperfusion (I/R) injury accounts for about 50% of the infarcted mass. In this cont...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular drugs and therapy 2019-06, Vol.33 (3), p.371-381
Main Authors: Sposito, Andrei C., Carmo, Helison R., Barreto, Joaquim, Sun, Lufan, Carvalho, Luiz Sergio F., Feinstein, Steve B., Zanotti, Ilaria, Kontush, Anatol, Remaley, Alan
Format: Article
Language:English
Subjects:
Animal models
Animals
Apolipoprotein A-I - blood
Apolipoproteins
Cardiology
Cell death
Dyslipidemias - blood
Dyslipidemias - genetics
Dyslipidemias - therapy
Genetic Therapy - adverse effects
Heart attacks
High density lipoprotein
Humans
Hypolipidemic Agents - adverse effects
Hypolipidemic Agents - therapeutic use
Injury prevention
Ischemia
Lethality
Life Sciences
Lipoproteins
Lipoproteins, HDL - adverse effects
Lipoproteins, HDL - genetics
Lipoproteins, HDL - therapeutic use
Medicine
Medicine & Public Health
Molecular Mimicry
Myocardial infarction
Myocardial Infarction - blood
Myocardial Infarction - genetics
Myocardial Infarction - prevention & control
Myocardial Reperfusion Injury - blood
Myocardial Reperfusion Injury - genetics
Myocardial Reperfusion Injury - prevention & control
Peptides
Peptides - adverse effects
Peptides - therapeutic use
Phospholipids
Reperfusion
Review Article
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It is now apparent that a variety of deleterious mechanisms intrinsic to myocardial infarction (MI) exists and underlies its high residual lethality. Indeed, despite effective coronary patency therapies, ischemia and reperfusion (I/R) injury accounts for about 50% of the infarcted mass. In this context, recent studies in animal models have demonstrated that coronary reperfusion with high-density lipoproteins (HDL) may reduce MI size in up to 30%. A spectrum of mechanisms mediated by either HDL-related apolipoproteins or phospholipids attenuates myocardial cell death. Hence, promising therapeutic approaches such as infusion of reconstituted HDL particles, new HDL by genomic therapy, or the infusion of apoA-I mimetic peptides have been sought as a way of ensuring protection against I/R injury. In this review, we will explore the limitations and potential therapeutic effects of HDL therapies during the acute phase of MI.
ISSN:0920-3206
1573-7241
DOI:10.1007/s10557-019-06865-1